Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages 152-160

  Massanella, Marta ^a   Esteve, Anna ^b   Buzón, Maria J ^a   Llibre, Josep M ^a   Puertas, Maria C ^a   Gatell, Josep M ^c   Domingo, Pere ^d   Stevenson, Mario ^e   Clotet, Bonaventura ^a   Martinez Picado, Javier ^a,f   Blanco, Julià ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Center for Epidemiological Studies on STI and HIV AIDS of Catalonia   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Hospital Sant Pau   (Spain)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

CD38; HIV 1 eradication; HIV 1 integrase; Viral Reservoir

Indexed keywords

RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD38 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; DYNAMICS; EPISOME; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REBOUND; TREATMENT WITHDRAWAL; BIOSYNTHESIS; BLOOD; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; PYRROLIDINONES; RNA, VIRAL; VIRAL LOAD;

MLCS; MLOWN;

EID: 84879774999     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318289439a     Document Type: Article

References (44)

1. Gougeon M, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 1996;156: 3509-3520.
2. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest. 2000;105:R1-R8.
3. Mocroft A, Bofill M, Lipman M, et al. CD8+, CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:158-162.
4. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS. 1996;10:827-834.
5. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Ret-rovirol. 1998;18:332-340.
6. Benito JM, López M, Lozano S, et al. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:227-233.
7. Steel A, Cox AE, Shamji MH, et al. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation. Antivir Ther. 2007;12:971-975.
8. Hunt P, Martin J, Sinclair E. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on anti-retroviral therapy. J Infect Dis. 2011;203:1474-1483.
9. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
10. Byakwaga H, Kelly M, Purcell DFJ, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis. 2011;204:1532-1540.
11. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879-3884.
12. Peterson S, Reid AP, Kim S, et al. Treatment implications of the latent reservoir for HIV-1. Adv Pharmacol. 2007;55:411-425.
13. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008;122:22-28.
14. Gutiérrez C, Díaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011;6:e27864.
15. Kolber MA, Saenz MO, Tanner TJ, et al. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clin Immunol. 2008;126:315-321.
16. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
17. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203:960-968.
18. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7:e1000321.
19. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204:1936-1945.
20. Yukl SA, Shergill AK, Mcquaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010; 24:2451-2460.
21. Vallejo A, Gutiérrez C, Hernández-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS. 2012;26:1885-1894.
22. Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17:355-364.
23. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS. 2012;26:2285-2293.
24. Sharkey M, Triques K, Kuritzkes DR, et al. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol. 2005;79:5203-5210.
25. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460-465.
26. Besson GJ, McMahon D, Maldarelli F, et al. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis. 2012; 54:451-453.
27. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202:1553-1561.
28. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;59:229-235.
29. Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-con-taining antiretroviral therapy. J Infect Dis. 2010;201:293-296.
30. Massanella M, Tural C, Papagno L, et al. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther. 2010;15:333-342.
31. Garrido C, Rallón N, Soriano V, et al. Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. AIDS. 2012;26:551-557.
32. Kimmig S, Przybylski GK, Schmidt CA, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195:789-794.
33. Tilling R, Kinloch S, Goh L-E, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;16:589-596.
34. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83:11407-11411.
35. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol. 2008;126:235-242.
36. Rodriguez B, Lederman MM, Jiang W, et al. Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. AIDS. 2006;20:1379-1389.
37. Steel A, John L, Shamji MH, et al. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med. 2008;9:118-125.
38. Buzon MJ, Codoñer FM, Frost SDW, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog. 2011;7:e1002314.
39. Fletcher CV. Overcoming pharmacologic sanctuaries. [Paper 108]. Presented at: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, 2012.
40. Catalfamo M, Di Mascio M, Hu Z, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A. 2008;105:19851-19856.
41. Catalfamo M, Wilhelm C, Tcheung L, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol. 2011;186:2106-2116.
42. Autran B. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997; 277:112-116.
43. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208-214.
44. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.